About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Press Releases
Our latest news and press releases
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
2020
28
Sep 2022
16:25 E.S.T.
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
Read more
01
Sep 2022
16:30 E.S.T.
Cellectis Announces Participation in Four Upcoming Investor Conferences in September
Read more
04
Aug 2022
16:30 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
Read more
01
Aug 2022
16:30 E.S.T.
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
Read more
28
Jul 2022
16:30 E.S.T.
Cellectis to Report Second Quarter 2022 Financial Results
Read more
30
Jun 2022
05:00 E.S.T.
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
Read more
Prev
1
2
3
4
5
Next